ReviewLeukemia2001
AC133 expression in human stem cells.
Review in Leukemia, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 169 citations in OpenAlex.
- COMPARE-AMI trial: comparison of intracoronary injection of CD133+ bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction: study rationale and design.Journal of cardiovascular translational research · 2010Trial
- Trial
- Targeted Radionuclide Therapy Using a Lutetium-177 Labeled Human Anti-CD133 Antibody.Molecular imaging and biology · 2025Article
- Circulating CD133+/–CD34– Have Increased c-Turkish journal of haematology : official journal of Turkish Society of Haematology · 2023Article
- MRI Tracking of Marine Proliferating Cells In Vivo Using Anti-Oct4 Antibody-Conjugated Iron Nanoparticles for Precision in Regenerative Medicine.Biosensors · 2023Article
- All-Trans Retinoic Acid Fosters the Multifarious U87MG Cell Line as a Model of Glioblastoma.Brain sciences · 2021Article
- Role of Lipid Rafts in Hematopoietic Stem Cells Homing, Mobilization, Hibernation, and Differentiation.Cells · 2019Review
- Repopulating hematopoietic stem cells from steady-state blood before and afterHaematologica · 2018Article
- Neuroblastoma Origin and Therapeutic Targets for Immunotherapy.Journal of immunology research · 2018Review
- MicroRNA-141 inhibits tumor growth and minimizes therapy resistance in colorectal cancer.Molecular medicine reports · 2017Article
- CD133 marks a stem cell population that drives human primary myelofibrosis.Haematologica · 2015Article
- Specific detection of CD133-positive tumor cells with iron oxide nanoparticles labeling using noninvasive molecular magnetic resonance imaging.International journal of nanomedicine · 2015Article
- Transplantation of mesenchymal stem cells into the renal medulla attenuated salt-sensitive hypertension in Dahl S rat.Journal of molecular medicine (Berlin, Germany) · 2014Article
- CD133 is a modifier of hematopoietic progenitor frequencies but is dispensable for the maintenance of mouse hematopoietic stem cells.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Clinical trials of cardiac repair with adult bone marrow- derived cells.Methods in molecular biology (Clifton, N.J.) · 2013Article
- Current strategies for identification of glioma stem cells: adequate or unsatisfactory?Journal of oncology · 2012Article
- CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope.The Journal of biological chemistry · 2011Article
- Cancer stem cell-related factors are associated with the efficacy of pre-operative chemoradiotherapy for locally advanced rectal cancer.Experimental and therapeutic medicine · 2011Article
- Proteome of human colon cancer stem cells: a comparative analysis.World journal of gastroenterology · 2011Article
- One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133 Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction.Bone marrow research · 2011Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Expression of cell surface markers on human hematopoietic cells has provided a method for characterizing subsets of cells with distinct biological functions. This is largely due to the ability to separate highly purified subpopulations of cells for comparative analysis. Relationships between the cell surface phenotype of these subpopulations and their proliferative and differentiative capacity have been instrumental in defining the hierarchical organization of cells comprising the human hematopoietic system. The identification and isolation of human hematopoietic cells expressing AC133, combined with use of in vitro and in vivo assays, has provided novel insights into the hematopoietic progenitor and stem cell compartment in the human. More recent studies have offered evidence that AC133 expression is not limited to primitive blood cells, but also defines unique cell populations in non-hematopoietic tissues. These findings will be reviewed here in the context of human hematopoiesis and the potential role and utility of AC133 expression in the human.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.